(RTTNews) - United Therapeutics Corp (UTHR) reported earnings for third quarter that Dropped, from the same period last year

United Therapeutics Corp Reports Drop In Q3 Profit 

On October 21, 2026, the Board of Directors of United Therapeutics Corporation approved a share repurchase program authorizing the purchase of up to $2.0 billion of the Company’s common stock. This authorization will remain in effect for a one-year period ending October 21,

United Therapeutics Corporation Announces $2.0 billion Share Repurchase Program

(RTTNews) - United Therapeutics (UTHR) announced the FDA has granted clearance under the investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD. The phase 2, 16-week, double blind SUMMIT study will evaluate the safety and tol

United: FDA Grants Clearance To Proceed With SUMMIT Trial Of Treprostinil SMI In PH-COPD 

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $363.3 million dollar inflow -- that's a 3.8% increase week

XBI, IOVA, SYRE, UTHR: ETF Inflow Alert

(RTTNews) - Liquidia Corp. (LQDA), a biopharmaceutical company, announced that it has entered into a global settlement agreement with United Therapeutics Corp. (UTHR) resolving all six pending litigation matters between the companies.

Liquidia Settles All Litigation With United Therapeutics; Shares Rise 

Check out the companies making headlines yesterday:

Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation News